Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1175646.RAiyoKOkXTe3XAFXThbWsFjeyZhEG2Y_CGodDeFr0uu34130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1175646.RAiyoKOkXTe3XAFXThbWsFjeyZhEG2Y_CGodDeFr0uu34130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1175646.RAiyoKOkXTe3XAFXThbWsFjeyZhEG2Y_CGodDeFr0uu34130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1175646.RAiyoKOkXTe3XAFXThbWsFjeyZhEG2Y_CGodDeFr0uu34130_provenance.
- NP1175646.RAiyoKOkXTe3XAFXThbWsFjeyZhEG2Y_CGodDeFr0uu34130_assertion description "[LUX-Lung 3 was a pivotal randomized Phase III study that recently led to the approval of afatinib (Gilotrif) in several countries for treatment of patients with metastatic NSCLC harboring somatic EGFR gene mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1175646.RAiyoKOkXTe3XAFXThbWsFjeyZhEG2Y_CGodDeFr0uu34130_provenance.
- NP1175646.RAiyoKOkXTe3XAFXThbWsFjeyZhEG2Y_CGodDeFr0uu34130_assertion evidence source_evidence_literature NP1175646.RAiyoKOkXTe3XAFXThbWsFjeyZhEG2Y_CGodDeFr0uu34130_provenance.
- NP1175646.RAiyoKOkXTe3XAFXThbWsFjeyZhEG2Y_CGodDeFr0uu34130_assertion SIO_000772 24754585 NP1175646.RAiyoKOkXTe3XAFXThbWsFjeyZhEG2Y_CGodDeFr0uu34130_provenance.
- NP1175646.RAiyoKOkXTe3XAFXThbWsFjeyZhEG2Y_CGodDeFr0uu34130_assertion wasDerivedFrom befree-2016 NP1175646.RAiyoKOkXTe3XAFXThbWsFjeyZhEG2Y_CGodDeFr0uu34130_provenance.
- NP1175646.RAiyoKOkXTe3XAFXThbWsFjeyZhEG2Y_CGodDeFr0uu34130_assertion wasGeneratedBy ECO_0000203 NP1175646.RAiyoKOkXTe3XAFXThbWsFjeyZhEG2Y_CGodDeFr0uu34130_provenance.
- befree-2016 importedOn "2016-02-19" NP1175646.RAiyoKOkXTe3XAFXThbWsFjeyZhEG2Y_CGodDeFr0uu34130_provenance.